NDA 208215 · Gilead Sciences INC
Descovy
Emtricitabine, Tenofovir Alafenamide Fumarate · Oral · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
OrphanLast checked: Nov 20, 2026Latest source record: Jun 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Apr 4, 2016
Approved uses
7
Original approval plus efficacy supplements
Registered trials
684
198 Phase 3, 28 recruiting
FAERS reports
11,421
8,578 serious, 366 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION Severe acute exacerbations of hepatitis B (HBV) have been reported in individuals with HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of DESCOVY. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals with HBV who discontinue DESCOVY. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . DESCOVY used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been...
What it is approved for
From the label in effect Jul 7, 2026.
HIV-1 Treatment ( 1.1 ): DESCOVY is a two-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and adolescent patients weighing at least 35 kg. for the treatment of HIV-1 infection in pediatric patients weighing at least 14 kg to less than 35 kg in combination with other antiretroviral agents, including darunavir and cobicistat but not other protease inhibitors that require a CYP3A inhibitor. HIV-1 PrEP ( 1.2 ): DESCOVY is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex. Individuals must have a negative HIV-1 test immediately prior to initiating DESCOVY for HIV-1 PrEP. Limitations of Use ( 1.2 ): The indication does not include use of DESCOVY in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated. 1.1 Treatment of HIV-1 Infection DESCOVY is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and adolescent patients weighing at least 35 kg. DESCOVY is indicated for the treatment of HIV-1 infection in pediatric patients weighing at least 14 kg to less than 35 kg in combination with other antiretroviral agents, including darunavir and cobicistat but not other protease inhibitors that require a CYP3A inhibitor. 1.2 HIV-1 Pre-Exposure Prophylaxis (PrEP) DESCOVY is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk...
Mechanism: DESCOVY is a fixed dose combination of antiretroviral drugs emtricitabine (FTC) and tenofovir alafenamide (TAF) [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 20, 2025 Supplement 25 · Efficacy OrphanLabelMedication GuideLetter
- Jun 20, 2025 Supplement 23 · Efficacy OrphanLabelLetter
- Jan 7, 2022 Supplement 20 · Efficacy · priority review OrphanLetterLabel
- Dec 3, 2019 Supplement 11 · Efficacy LetterLabelMedication Guide
- Oct 3, 2019 Supplement 12 · Efficacy · priority review LabelLetterReview
- Sep 28, 2017 Supplement 5 · Efficacy · priority review LabelLetterPediatric Clinical Pharmacology Review
- Apr 4, 2016 Original approval · Type 4 - New Combination OrphanLabelReviewSummary Review
2 products under this application
- DESCOVY · EMTRICITABINE 200MG; TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB
- DESCOVY · EMTRICITABINE 120MG; TENOFOVIR ALAFENAMIDE FUMARATE EQ 15MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Emtricitabine" as an intervention, any sponsor and status, largest first.
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidencePivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01509508 · 28,153 participants · Start Mar 2012 · Primary completion Jun 2016
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV · For: HIV Infection
Sites: Hlabisa, South Africa
University of WashingtonAcademic, hospital or other
NCT04666792 · 25,457 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2024
Drug: PrEP · For: HIV Infections; Contraception; STI
Sites: Kisumu, Kenya
- Expanded PrEP Implementation in Communities in NSWPivotal-lookingCompleted
Kirby InstituteGovernment (non-federal)
NCT02870790 · 9,733 participants · Start Mar 2016 · Primary completion Mar 2019
Drug: TDF/FTC · For: HIV; STI
Sites: Canberra, Australia; Albury, Australia; Alexandria, Australia · 31 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02842086 · 5,399 participants · Start Sep 2, 2016 · Primary completion Jan 31, 2019
Drug: F/TAF; F/TDF and 2 more · For: Pre-Exposure Prophylaxis of HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 93 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
- Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in WomenPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00705679 · 5,029 participants · Start Aug 2009 · Primary completion Aug 2012
Drug: Emtricitabine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate placebo and 4 more · For: HIV Infections
Sites: Johannesburg, South Africa; Asherville, South Africa; Chatsworth, South Africa · 15 sites in all
- The Partners Scale-Up ProjectCompleted
University of WashingtonAcademic, hospital or other
NCT03052010 · 4,898 participants · Start Feb 6, 2017 · Primary completion Dec 15, 2020
Drug: PrEP; ART · For: HIV-1-infection
Sites: Kisumu, Kenya; Thika, Kenya
- Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant CouplesPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT00557245 · 4,758 participants · Start May 2008 · Primary completion Oct 2013
Drug: Tenofovir Disoproxil Fumarate (TDF); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and 1 more · For: HIV-1 Infections; HIV Infections
Sites: Eldoret, Kenya; Kisumu, Kenya; Nairobi, Kenya · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bone density decreased4,869
- chronic kidney disease2,890
- bone loss2,649
- osteonecrosis2,620
- multiple fractures2,442
- tooth loss2,330
- osteoporosis2,283
- renal failure2,267
- pain2,017
- emotional distress1,925
- renal injury1,886
- anxiety1,786
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 59 |
| 2017 | 267 |
| 2018 | 504 |
| 2019 | 971 |
| 2020 | 4,102 |
| 2021 | 1,706 |
| 2022 | 1,242 |
| 2023 | 707 |
| 2024 | 744 |
| 2025 | 781 |
| 2026 | 333 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Descovy (Emtricitabine/Tenofov Alafenam)
2024 spending
$545M
Beneficiaries
30,179
238,782 claims
Per beneficiary
$18,049
$72.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $557,919,940 |
| 2021 | $559,524,804 |
| 2022 | $574,036,753 |
| 2023 | $589,840,789 |
| 2024 | $544,696,050 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
Bekker LG, Das M, Abdool Karim Q, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
O Murchu E, Marshall L, Teljeur C, et al. · BMJ Open 2022 · Meta-Analysis, Systematic Review
- Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W, Zhao S, Wu Y, et al. · JMIR Public Health Surveill 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Multicenter Study
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, Molina JM, Thompson MA, et al. · Lancet 2020 · Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL, Lu Y, Yoshida K, et al. · Lancet Infect Dis 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.